Genentech, Inc.

Denali Therapeutics Inc.

Washington University

Genetech, Inc.

Adimab, LLC

F. Hoffmann-la Roche Ag

Mark S Dennis

Xiaocheng Chen

Andrew G Polson

Jagath Reddy Junutula

Yvonne M Chen

Yin Sheng Zhang

Ryan Jefferson Watts

Bing Zheng

Joy Yu Zuchero

Paul Polakis

Kristi Elkins

Allen J Ebens

Robert A Lazarus

Adam P Silverman

Mary A Mathieu

Robert F Kelley

Bonnee Rubinfeld

David Dornan

Lawren Wu

Jessica Couch

Gregory Alan Lazar

Sherman Fong

James A Ernst

Jasvinder Atwal

Liping L Sun

Yan Wu

Mark X Sliwkowski

Thomas Pillow

Anan Chuntharapai

Mihalis S Kariolis

Mercedesz Balazs

Terence Wong

Ankita Srivastava

Gail Lewis Phillips

Hans Brightbill

Aya Jakobovits

Luc Roland Desnoyers

Wei-Ching Liang

Susan D Spencer

Dorothy French

James T Koerber

Teemu T Junttila

William Mallet

Mason Lu

Cecilia Pui Chi Chiu

Robert C Wells

Janet K Jackman

Tracy Staton

Saroja Ramanujan

Tangsheng Yi

Jana Seymour Ulmer

Kathila Rajapaksa

Andrew C Chan

Judy C Young

Devin Tesar

Hong Jiang

Rachel Prorok

Joshua I Park

Bettina Van Lengerich

Andy Chan

Karen Billeci

Thu Nga Bien-Ly

Simon Williams

Bryan Irving

Jill Fredrickson

Kathryn M Monroe

Jing Guo

James Wolter Ernst

Ji Li

Suzanna J Scales

Henry R Maun

Henry Bernard Lowman

Steven R Leong

Isidro Hotzel

Weilan Ye

David Michael Holtzman

Yvonne Man-Yee Chen

Warren L DeLano

Rinkan Shukla

Zhong Zheng

David Aaron Estell

Germaine G Fuh

Michael Feldhaus

David Richard Light

Chingwei Vivian Lee

Eric Krauland

Jan Marik

Cathal S Mahon

Yichin Liu

Rishi Rakhit

Lesley Ann Kane

Yunhua Joy Yu

Charles Eigenbrot

Do Jin Kim

Yunhua Yu Zuchero

Jennifer A Getz

Mary Mathieu

Sherie Duncan

Joseph W Lewcock

Fan Liao

In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.

Anti-TREM2 antibodies and methods of use thereof

Provided herein are polypeptides that bind to a transferrin receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell.

Methods of engineering transferrin receptor binding polypeptides

The invention provides compositions including anti-tryptase antibodies and pharmaceutical compositions thereof, as well as methods of using the same.

Anti-tryptase antibodies, compositions thereof, and uses thereof

The present disclosure encompasses compositions and methods for effectively treating at least one symptom or sign of Aß plaque or cerebral amyloid angiopathy (CAA) associated symptoms, or for decreasing amyloid plaque load or CAA load. The method comprises administering an effective amount of an anti-ApoE antibody to a mammalian subject, such as to a human.

Anti-ApoE antibodies

The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.

Humanized anti-CD79B antibodies and immunoconjugates and methods of use

Engineered transferrin receptor binding polypeptides

In one aspect, antibodies that specifically bind to a human BACE1 protein are provided herein. In some embodiments, the antibodies contain modifications that reduce effector function, extend serum stability or serum half-life, or promote heterodimerization. In other aspects, bispecific antibodies and pharmaceutical compositions comprising antibodies that bind to human BACE1 protein are provided herein. Methods for inhibiting amyloid-&#x3b2; formation and/or aggregation, inhibiting amyloid plaque formation, and treating neurodegenerative diseases are also provided herein.

Anti-BACE1 antibodies and methods of use thereof

The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.

Anti-CD3 antibodies and methods of use

In some aspects, the present invention provides chimeric transferrin receptor (TfR) polynucleotides and polypeptides. In other aspects, this invention provides chimeric TfR transgenic animal models and methods of using the animal models to identify therapeutics that can cross the blood-brain barrier.

Transferrin receptor transgenic models

The present invention relates to anti-CLL-1 antibodies including anti-CLL-1 antibodies comprising a CLL-1 binding domain and a CD3 binding domain (e.g., anti-CLL-1/CD3 T cell dependent bispecific (TDB) antibody) and methods of using the same.

Anti-CLL-1 antibodies and methods of use

In one aspect, antibodies that specifically bind to a human Tau protein are provided. In some embodiments, an anti-Tau antibody recognizes an epitope within residues 111-125 of full-length human Tau, an epitope within residues 251-270 and/or residues 346-360 of full-length human Tau, or an epitope within residues 186-205 of full-length human Tau. In some embodiments, an anti-Tau antibody specifically binds to phosphorylated human Tau, unphosphorylated human Tau, and/or multiple splice isoforms of human Tau. An anti-Tau antibody disclosed herein may also include one or two modified Fc polypeptides.

Anti-Tau antibodies and methods of use thereof

The present invention relates to compositions and methods for improving the safety of blood-brain barrier receptor-mediated blood-brain barrier transport.

Methods for improving safety of blood-brain barrier transport

Growing community of inventors

San Carlos, CA, United States of America

Mark S Dennis